XML 62 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis
The following table sets forth the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):
December 31, 2023
Level 1Level 2Level 3Total
Financial assets:
Money market funds
$62,075 $— $— $62,075 
U.S. Treasury securities
— 374,356 — 374,356 
U.S. government agency securities
— 48,750 — 48,750 
Corporate debt securities
— 59,606 — 59,606 
Total financial assets
$62,075 $482,712 $— $544,787 
Financial liabilities:
Success payment liabilities
$— $— $1,576 $1,576 
Total financial liabilities
$— $— $1,576 $1,576 
December 31, 2022
Level 1Level 2Level 3Total
Financial assets:
Money market funds
$67,970 $— $— $67,970 
U.S. Treasury securities
— 271,799 — 271,799 
U.S. government agency securities
— 134,045 — 134,045 
Corporate debt securities
— 220,681 — 220,681 
Total financial assets
$67,970 $626,525 $— $694,495 
Financial liabilities:
Success payment liabilities
$— $— $4,356 $4,356 
Total financial liabilities
$— $— $4,356 $4,356 
Schedule of Estimated Fair Value of Success Payment Liability Assumptions
The following assumptions were incorporated into the calculation of the estimated fair value of the Fred Hutch success payment liability:
December 31,
20232022
Fair value of common stock
$1.94$3.47
Risk-free interest rate
3.51% - 5.19%
3.58% - 4.65%
Expected volatility
80.0 %80.0 %
Expected term (in years)
0.46 - 3.97
0.46 - 4.97
The following assumptions were incorporated into the calculation of the estimated fair value of the Stanford success payment liability:
December 31,
20232022
Fair value of common stock
$1.94$3.47
Risk-free interest rate
3.51% - 5.19%
3.58% - 4.65%
Expected volatility
80.0 %80.0 %
Expected term (in years)
0.46 - 5.75
0.46 - 6.75
Schedule of Changes in the Estimated Fair Value of Level 3 Financial Assets
The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets and liabilities (in thousands):
Equity Warrant
Investment
Success Payment
Liabilities
Balance at December 31, 2021
$1,067 $9,486 
Change in fair value (1)
(1,067)(5,130)
Balance at December 31, 2022
— 4,356 
Change in fair value (1)
— (2,780)
Balance at December 31, 2023
$— $1,576 
__________
(1)The change in the fair value associated with the Fred Hutch success payment liabilities for the year ended December 31, 2023 is recorded in other income (expense), net. The change in the fair value associated with the Fred Hutch success payment liabilities for the year ended December 31, 2022, and the change in the fair value associated with the Stanford success payment liabilities for the years ended December 31, 2023 and 2022, respectively, are recorded as research and development expenses. (See Note 3, License, Collaboration and Success Payment Agreements). Changes in fair value associated with the equity warrant investment held are recorded in other income (expense), net.
Schedule of Changes in the Estimated Fair Value of Level 3 Financial Liabilities
The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets and liabilities (in thousands):
Equity Warrant
Investment
Success Payment
Liabilities
Balance at December 31, 2021
$1,067 $9,486 
Change in fair value (1)
(1,067)(5,130)
Balance at December 31, 2022
— 4,356 
Change in fair value (1)
— (2,780)
Balance at December 31, 2023
$— $1,576 
__________
(1)The change in the fair value associated with the Fred Hutch success payment liabilities for the year ended December 31, 2023 is recorded in other income (expense), net. The change in the fair value associated with the Fred Hutch success payment liabilities for the year ended December 31, 2022, and the change in the fair value associated with the Stanford success payment liabilities for the years ended December 31, 2023 and 2022, respectively, are recorded as research and development expenses. (See Note 3, License, Collaboration and Success Payment Agreements). Changes in fair value associated with the equity warrant investment held are recorded in other income (expense), net.